AU2009246112B2 - Method of treating chronic heart failure - Google Patents

Method of treating chronic heart failure Download PDF

Info

Publication number
AU2009246112B2
AU2009246112B2 AU2009246112A AU2009246112A AU2009246112B2 AU 2009246112 B2 AU2009246112 B2 AU 2009246112B2 AU 2009246112 A AU2009246112 A AU 2009246112A AU 2009246112 A AU2009246112 A AU 2009246112A AU 2009246112 B2 AU2009246112 B2 AU 2009246112B2
Authority
AU
Australia
Prior art keywords
relaxin
heart failure
heart
subject
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009246112A
Other languages
English (en)
Other versions
AU2009246112A1 (en
Inventor
Thomas Dschietzig
Dennis R. Stewart
Sam L. Teichman
Elaine Unemori
Martha Jo Whitehouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corthera Inc
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of AU2009246112A1 publication Critical patent/AU2009246112A1/en
Application granted granted Critical
Publication of AU2009246112B2 publication Critical patent/AU2009246112B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2009246112A 2008-05-16 2009-05-15 Method of treating chronic heart failure Ceased AU2009246112B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US61/127,889 2008-05-16
US19054508P 2008-08-28 2008-08-28
US61/190,545 2008-08-28
US20124008P 2008-12-08 2008-12-08
US61/201,240 2008-12-08
PCT/US2009/044247 WO2009140657A2 (en) 2008-05-16 2009-05-15 Method of treating chronic heart failure

Publications (2)

Publication Number Publication Date
AU2009246112A1 AU2009246112A1 (en) 2009-11-19
AU2009246112B2 true AU2009246112B2 (en) 2013-05-02

Family

ID=41319370

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009246112A Ceased AU2009246112B2 (en) 2008-05-16 2009-05-15 Method of treating chronic heart failure

Country Status (10)

Country Link
US (3) US20110144019A1 (https=)
EP (2) EP3150219A1 (https=)
JP (3) JP2011520917A (https=)
CN (2) CN102026649A (https=)
AU (1) AU2009246112B2 (https=)
BR (1) BRPI0912559A2 (https=)
CA (1) CA2724535A1 (https=)
MX (2) MX2010012502A (https=)
RU (1) RU2512933C2 (https=)
WO (1) WO2009140657A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036679A (zh) 2008-05-16 2011-04-27 科尔泰拉公司 用松弛素治疗与急性心力衰竭相关的呼吸困难
BR112012022654A2 (pt) * 2010-03-10 2016-11-01 Univ Florida modulação de aquaporinas com relaxina
WO2012072681A1 (en) * 2010-12-01 2012-06-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Diagnostic and treatment of chronic heart failure
JP2014529293A (ja) * 2011-07-08 2014-11-06 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ レラキシンを放出する融合タンパク質およびその使用
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−２を調製する方法
US10493131B2 (en) 2011-08-31 2019-12-03 University Of Florida Research Foundation, Incorporated Materials and methods for modulating activity of bone marrow derived cells
US20140364334A1 (en) * 2011-12-21 2014-12-11 Nuclea Biotechnologies, Inc. Congestive heart failure biomarkers
CN108310396B (zh) 2012-02-14 2022-07-15 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
US20140213520A1 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
MX2016005545A (es) * 2013-11-07 2016-10-03 Shanghai hengrui pharmaceutical co ltd Analogo de la relaxina humana, composicion farmaceutica del mismo y aplicacion farmaceutica del mismo.
US10500227B2 (en) * 2014-12-03 2019-12-10 University Of Cincinnati Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease
WO2017100540A2 (en) 2015-12-09 2017-06-15 The California Institute For Biomedical Research Relaxin immunoglobulin fusion proteins and methods of use
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
US20220008508A1 (en) * 2018-11-20 2022-01-13 Universität Heidelberg Relaxin receptor 1 for use in treatment and prevention of heart failure
AU2020382102B2 (en) 2019-11-16 2026-02-26 Relaxera Pharmazeutische Gmbh & Co. Kg Medical composition for treating cardiac wasting and cachexia
CN116406297A (zh) * 2020-08-05 2023-07-07 阿斯克肋匹奥生物制药公司 治疗心脏疾患和充血性心力衰竭以及施用aav载体的方法
RU2748529C1 (ru) * 2020-09-01 2021-05-26 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ определения этиологии хронической сердечной недостаточности
TW202438534A (zh) * 2022-12-09 2024-10-01 瑞典商阿斯特捷利康公司 使用異二聚物鬆弛素融合體的給藥方案

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
WO2002040500A2 (en) * 2000-11-16 2002-05-23 Immundiagnostik Ag Method of prognosis and diagnosis of congestive heart failure

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
EP0707650B1 (en) 1993-06-21 2003-05-21 Genentech, Inc. Process for producing human relaxin
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
RU2213559C2 (ru) * 2000-01-26 2003-10-10 Тюменская государственная медицинская академия Способ лечения больных хронической сердечной недостаточностью на фоне ишемической болезни сердца
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
CN1968717B (zh) * 2004-03-30 2013-08-21 延世大学教产学协力团 含有松弛素基因的基因送递系统和使用松弛素的药物组合物
US20080077025A1 (en) * 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
US8492329B2 (en) 2007-07-12 2013-07-23 Compugen Ltd. Bioactive peptides and methods of using same
CN102036679A (zh) * 2008-05-16 2011-04-27 科尔泰拉公司 用松弛素治疗与急性心力衰竭相关的呼吸困难

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
WO2002040500A2 (en) * 2000-11-16 2002-05-23 Immundiagnostik Ag Method of prognosis and diagnosis of congestive heart failure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"View of NCT00520806 on 2008_04_23" [retrieved on 7 September 2011] Retrieved from the internet published 23 April 2008 *

Also Published As

Publication number Publication date
MX2010012502A (es) 2011-04-11
EP3150219A1 (en) 2017-04-05
US20140005112A1 (en) 2014-01-02
JP2014237648A (ja) 2014-12-18
JP2011520917A (ja) 2011-07-21
WO2009140657A3 (en) 2010-01-07
CN102026649A (zh) 2011-04-20
EP2288366A2 (en) 2011-03-02
CA2724535A1 (en) 2009-11-19
WO2009140657A2 (en) 2009-11-19
RU2512933C2 (ru) 2014-04-10
EP2288366A4 (en) 2012-05-02
CN104815319A (zh) 2015-08-05
US20110144019A1 (en) 2011-06-16
MX336145B (es) 2016-01-08
RU2010151470A (ru) 2012-06-27
US20160287672A1 (en) 2016-10-06
BRPI0912559A2 (pt) 2015-10-13
JP2017061453A (ja) 2017-03-30
AU2009246112A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
AU2009246112B2 (en) Method of treating chronic heart failure
US9579363B2 (en) Method of lowering mortality
AU2013201629A1 (en) Treating dyspnea associated with acute heart failure with relaxin
HK1151229B (en) Relaxin for use in treating of dyspnea associated with acute heart failure

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired